Bristol-Myers Squibb: No Respect For Blowout Earnings

Bristol-Myers Squibb (BMY) has recently underperformed the broader market, down 7.7%, primarily due to investor concerns over new U.S. healthcare policies impacting drug pricing and Medicaid. Despite this, BMY reported a double-beat in FQ2'25 with revenues of $12.3B and raised its FY2025 guidance to $47B, driven by its accelerating Growth Portfolio, which now comprises 53.6% of total revenues and includes a significant $11.1B oncology licensing deal with BioNTech. The stock trades at a deeply discounted 7.28x FWD P/E, well below its historical averages and sector median, while offering a compelling 5.39% dividend yield. While near-term stock underperformance may continue given regulatory headwinds, the article maintains a Buy rating, viewing BMY as a compelling income investment with substantial long-term capital appreciation potential as its R&D and M&A efforts are expected to deliver significant growth later this decade.

Analysis

Bristol-Myers Squibb (BMY) presents a clear divergence between its operational performance and recent stock price action. The stock has underperformed the broader market by declining 7.7% and has fallen 11.3% from its July 2025 peak, primarily due to sector-wide regulatory headwinds, including potential US drug pricing reforms and reduced Medicaid funding. Despite this market pessimism, BMY delivered a double-beat in FQ2'25 with revenues of $12.3 billion and raised its full-year 2025 guidance to $47 billion in revenue. This fundamental strength is driven by its rapidly expanding Growth Portfolio, which grew 17.8% year-over-year and now constitutes 53.6% of total revenue, effectively offsetting the 14% YoY decline in its legacy portfolio. This strategic pivot is further reinforced by an $11.1 billion licensing deal with BioNTech for a promising oncology candidate. The market's focus on macro risks has compressed BMY's valuation to a deeply discounted 7.28x forward P/E, significantly below its 5-year average of 18.62x. This has, in turn, elevated its forward dividend yield to a compelling 5.39%, which is well-supported by annualized operating cash flows of $11.74 billion.

Key Decisions for Investors

• Income-focused investors should evaluate BMY for its compelling 5.39% forward dividend yield, which appears secure given the company's strong operating cash flow and moderating debt levels.
• Value investors may find the current 7.28x forward P/E multiple an attractive entry point, but must be prepared for a prolonged holding period as significant capital appreciation is contingent on the M&A and R&D pipeline delivering results later in the decade.
• Given the significant regulatory headwinds and negative stock momentum, investors should monitor for a technical price floor before initiating or adding to positions and closely track legislative outcomes on US drug pricing, which is the primary overhang on valuation.